Porex has a history of developing, manufacturing and distributing bioimplantable porous polyethylene products for reconstructive surgery of the head and face. The product portfolio will complement Stryker’s current hold in the craniomaxillofacial market.
The terms of the transaction were not disclosed. However, it is expected to be neutral to Stryker’s 2010 and 2011 earnings per share and then accretive thereafter.
Read the Stryker news release on the transaction.
Read other coverage on Stryker:
– Stryker Acquires Boston Scientific Corp.’s Neurovascular Business for $1.5B
– Stryker Reports a 7% Net Sales Increase for 3Q 2010
– Stryker Acquires Gaymar Industries for $150M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
